DA Davidson reiterated coverage on Medifast with a new price target
$MED
Packaged Foods
Consumer Staples
DA Davidson reiterated coverage of Medifast with a rating of Buy and set a new price target of $341.00 from $349.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $16.50 → $17.00 | Underperform → Neutral | DA Davidson |
| 6/5/2024 | $25.00 → $17.50 | Neutral → Underperform | DA Davidson |
| 10/13/2023 | $82.00 | Equal-Weight | Stephens |
| 11/4/2022 | $278.00 → $106.00 | Buy → Neutral | DA Davidson |
| 8/4/2022 | $345.00 → $150.00 | Buy → Hold | Jefferies |
| 2/24/2022 | $349.00 → $341.00 | Buy | DA Davidson |
| 11/8/2021 | $395.00 → $349.00 | Buy | DA Davidson |
3/A - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026 on Monday, August 3, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 3, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at ht
The leading health and wellness company unveils an evolutionary transformation from weight loss to optimal metabolic health, powered by breakthrough science and human connection Medifast, Inc. (NYSE:MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transformation, and the beginning of a new era focused
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026)Women in midlife who focus on scale weight alone may be measuring the wrong thing: visceral fat and lean mass retention are the markers that reflect metabolic progressSleep disruption, elevated stress, and hormonal variability during midlife create conditions where self-directed programs stallThe coaching gap in weight loss outcomes becomes more significant during hormonal transition, when behavioral disruptions make self-directed programs harder to sustain BALTIMORE, MD, June
DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously
DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously
Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00
8-K - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026 on Monday, August 3, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 3, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at ht
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or
Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a
Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)